Allegra-D 24 hour
Selected indexed studies
- The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D 24-Hour--original formulation). (Pharmacoepidemiol Drug Saf, 2004) [PMID:14971120]
- Clinical pharmacology of new histamine H1 receptor antagonists. (Clin Pharmacokinet, 1999) [PMID:10384858]
- Desloratadine: an update of its efficacy in the management of allergic disorders. (Drugs, 2003) [PMID:12962522]
_Worker-drafted node — pending editorial review._
Connections
Allegra-D 24 hour is a side effect of
Sources
- Desloratadine: an update of its efficacy in the management of allergic disorders. (2003) pubmed
- The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D 24-Hour--original formulation). (2004) pubmed
- Safety and tolerability of treatments for allergic rhinitis in children. (2004) pubmed
- Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. (1998) pubmed
- Clinical pharmacology of new histamine H1 receptor antagonists. (1999) pubmed
- Translating the evidence on atypical depression into clinical practice. (2007) pubmed
- Design of a 24-hour controlled porosity osmotic pump system containing PVP: formulation variables. (2009) pubmed
- Esophageal retention of loratadine plus pseudoephedrine extended-release tablets (Claritin-D 24 Hour). (1998) pubmed
- Twenty-four hours of activity of cetirizine and fexofenadine in the skin. (2001) pubmed
- Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers. (2020) pubmed